These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7847776)

  • 41. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
    Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder.
    May M; Nitzke T; Helke C; Vogler H; Hoschke B
    Scand J Urol Nephrol; 2004; 38(3):231-5. PubMed ID: 15204377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
    Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
    J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Bladder cancer in elderly patients].
    Isaka S; Igarashi T; Akimoto S; Okano T; Shimazaki J; Matsuzaki O
    Hinyokika Kiyo; 1984 Dec; 30(12):1793-9. PubMed ID: 6532207
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical studies of patients with bladder tumors].
    Matsuura T; Sugiyama T; Tsujihashi H; Kato Y; Boku E; Kunikata S; Kanda H; Kataoka K; Nagai N; Kaneko S
    Hinyokika Kiyo; 1983 Jan; 29(1):23-30. PubMed ID: 6203375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of transitional cell carcinoma of the bladder.
    Murshidi MS
    Arch Esp Urol; 1989 Mar; 42(2):172-5. PubMed ID: 2735783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment methods as a prognostic factor in eight patients with urachal carcinoma].
    Yamada T; Fukui I; Sekine H; Kihara K; Oshima H
    Hinyokika Kiyo; 1991 Feb; 37(2):113-6. PubMed ID: 2048489
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Organ preservation in superficial bladder cancer.
    Oosterhof GO; Witjes JA; Debruyne FM
    Prog Clin Biol Res; 1991; 370():195-202. PubMed ID: 1924451
    [No Abstract]   [Full Text] [Related]  

  • 57. Management of primary bladder cancer by a multidisciplinary team.
    Collins WE; Catton GE; Hussey A; Baker RG; Last JM
    Can J Surg; 1979 Sep; 22(5):431-4. PubMed ID: 497911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Doxorubicin hypogastric artery infusion combined with hyperthermia therapy for transitional cell carcinoma of the bladder.
    Jacobs SC; Maddison FE; Lawson RK
    Cancer Treat Rep; 1981; 65(9-10):891-3. PubMed ID: 7273025
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Editorial Comment to Cancer death from non-muscle invasive bladder cancer: Report of the Japanese Urological Association of data from the 1999-2001 registry in Japan.
    Koga F
    Int J Urol; 2010 Nov; 17(11):913. PubMed ID: 20969638
    [No Abstract]   [Full Text] [Related]  

  • 60. [Interdisciplinary strategies for the treatment of bladder cancer].
    Bauer W; Lamche M; Schramek P
    Wien Med Wochenschr; 2007; 157(7-8):153-6. PubMed ID: 17492411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.